RBR-4mzcwpw尚未招募3 期
Topical Clobetasol as an adjunct treatment to 4% Hydroquinone in moderate to severe facial Melasma: a randomized, double-blind, controlled clinical trial
niversidade Estadual Paulista (UNESP)0 个研究点开始时间: 2022年12月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 60Y（—）
- 性别
- Female
入选标准
- •Women; age between 18 and 60 years old; with moderate to severe facial melasma or mMasi greater than 5; without treatment for at least 45 days except of the using of sunscreen
排除标准
- •Pregnant and lactating women; carriers of other concomitant facial dermatoses; dermatoses with photosensitivity; glaucoma; previous episode of perioral dermatitis; melasma with mMASI less than 5; history of hypersensitivity or local adverse reactions to the use of hydroquinone or clobetasol or any other component of the formulation described
研究者
相似试验
进行中（未招募）
1 期
Clinical study to assess the efficacy of Clobetasol mouth rinses in patientswith oral lichen planus.MedDRA version: 20.1Level: PTClassification code 10030983Term: Oral lichen planusSystem Organ Class: 10017947 - Gastrointestinal disordersOral lichen planusEUCTR2018-004222-28-SEMalmö University90
已完成
不适用
Comparison of efficacy of topical clobetasol 0.05% plus 5FU 5% cream vs. topical clobetasol 0.05% alone in the treatment of vitiligo.Vitiligo.vitiligoIRCT201203049198N2Isfahan Univercity of Medical Sciences45
已完成
不适用
Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis siccaH16.2H04.1KeratoconjunctivitisOther disorders of lacrimal glandDRKS00003269niversitätsklinikum Erlangen der Friedrich-Alexander Universität Erlangen-Nürnberg62
已完成
不适用
The use of a biologic topical haemostatic agent (TachoSil®) for the prevention of postoperative bleeding in patients on antithrombotic therapy undergoing thyroid surgeryISRCTN30172374niversity of Cagliari70
进行中（未招募）
不适用
Efficacy and Safety of Clobetasol propionate shampoo 0.05% used in association with an antifungal shampoo in the treatment of moderate to severe Scalp Seborrheic Dermatitis - ESCAPE - Scalp Seborrheic DermatitisEUCTR2008-005217-22-DEGalderma Research & Development320